共 50 条
- [41] A PROSPECTIVE PHASE II TRIAL OF STEREOTACTIC BODY RADIATION THERAPY IN NON-SURGICAL STAGE I NSCLC PATIENTS: FOCUS ON CANCER-SPECIFIC SURVIVAL RATES AND MEDIAN SURVIVAL TIMERADIOTHERAPY AND ONCOLOGY, 2010, 96 : S338 - S338Ricardi, U.Guarneri, A.Filippi, A. R.Botticella, A.Iftode, C.Levra, N. GiajMantovani, C.Ragona, R.
- [42] A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703)CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (01) : 117 - 127Fukumoto, Shin-ichiOizumi, SatoshiHarada, MasaoSukoh, NoriakiNakano, KosukeFuke, SatoshiSakakibara-Konishi, JunTakamura, KeiIto, KenichiroFujita, YukaNishigaki, YutakaHarada, ToshiyukiAkie, KenjiKinoshita, IchiroAmano, TorajiIsobe, HiroshiDosaka-Akita, HirotoshiNishimura, Masaharu
- [43] A RANDOMIZED PHASE II TRIAL OF CISPLATIN PLUS GEMCITABINE VERSUS CARBOPLATIN PLUS GEMCITABINE IN PATIENTS WITH COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER: HOKKAIDO LUNG CANCER CLINICAL STUDY GROUP TRIAL (HOT0703)ANNALS OF ONCOLOGY, 2014, 25Harada, T.Fukumoto, S.Harada, M.Nakano, K.Sukoh, N.Fuke, S.Asahina, H.Takamura, K.Yamamoto, M.Fujita, Y.Akie, K.Kinoshita, I.Oizumi, S.Akita, H.Isobe, H.Nishimura, M.
- [44] Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE TrialCLINICAL CANCER RESEARCH, 2020, 26 (13) : 3172 - 3181Mazieres, JulienBarlesi, FabriceRouquette, IsabelleMolinier, OlivierBesse, BenjaminMonnet, IsabelleAudigier-Valette, ClarisseToffart, Anne-ClaireRenault, Patrick AldoFraboulet, SeverineHiret, SandrineMennecier, BertrandDebieuvre, DidierWesteel, VirginieMasson, PhilippeMadroszyk-Flandin, AnnePichon, EricCortot, Alexis B.Amour, ElodieMorin, FranckZalcman, GerardMoro-Sibilot, DenisSouquet, Pierre-Jean
- [45] THE PREDICTORS OF EARLY RECURRENCE IN PATIENTS WITH COMPLETELY RESECTED P-STAGE I NON-SMALL CELL LUNG CANCERJOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S623 - S623Hata, KazunoriYoshida, JunjiIshii, GenichiroHirayama, ShuNKIMatsuwaki, RieMatsumura, YukiAokage, KeijuHishida, TomoyukiNagai, Kanji
- [46] Oral talactoferrin extends survival in patients with refractory NSCLC in a randomized, placebo-controlled, phase 2 trialJOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S360 - S360Parikh, Purvish M.Wang YenyunRanade, A. A.Vaid, A. K.Advani, S. H.Raghunadharao, D.Nag, S.Madhavan, J. P.Varadhachary, Atul
- [47] Oral talactoferrin extends survival in patients with refractory NSCLC in a randomized, placebo-controlled, phase 2 trialJOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Parikh, P. K.Wang, Y.Ranade, A. A.Vaid, A. K.Advani, S. H.Raghunadharao, D.Nag, S.Madhavan, J. P.Varadhachary, A.
- [48] A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703)Cancer Chemotherapy and Pharmacology, 2020, 86 : 117 - 127Shin-ichi FukumotoSatoshi OizumiMasao HaradaNoriaki SukohKosuke NakanoSatoshi FukeJun Sakakibara-KonishiKei TakamuraKenichiro ItoYuka FujitaYutaka NishigakiToshiyuki HaradaKenji AkieIchiro KinoshitaToraji AmanoHiroshi IsobeHirotoshi Dosaka-AkitaMasaharu Nishimura
- [49] Prognostic factors for post-recurrence survival in patients with completely resected Stage I non-small-cell lung cancerEUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2014, 45 (02) : 262 - 267Song, In HagYeom, Sung WonHeo, SeoheeChoi, Won SukYang, Hee ChulJheon, SanghoonKim, KwhanmienCho, Sukki
- [50] Adjuvant Erlotinib (E) Versus Placebo (P) for Completely Resected Stage IB-IIIA EGFR-Positive (IHC/FISH) Non-Small Cell Lung Cancer (NSCLC): RADIANT ResultsINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S2 - S3Altorki, N. K.O'brien, M. E. R.Eberhardt, W. E. E.Richardson, F. C.Wang, J.Foley, M. A.Horan, J. D.Shepherd, F. A.Kelly, K.